He is Professor Emeritus of Psychiatry and Human Behavior at Brown Medical School in Providence, Rhode Island.
One example is the Longitudinal Interval Follow-Up Evaluation (LIFE), which prospectively assesses psychopathology over time and has been used in over 1,000 research programs internationally.
[2] The recipient of over 25 NIMH grants, his studies lead to a paradigm shift in understanding that mood and anxiety disorders are not short-lived episodes, but are primarily chronic, recurrent and disabling illnesses, expressed across the lifespan; which provided evidence to the Surgeon Generals report that depression is one of the more devastating public health problems.
Keller was listed as the lead author in 2001 of a controversial paper on study 329, a clinical trial funded by SmithKline Beecham, known since 2000 as GlaxoSmithKline.
"[3] In fact, study 329 indicated otherwise for both efficacy and safety in treating teenagers, showing an increase in suicidality and emotional lability.